Nurse Destiny and Sandra were excellent
ATP increases [Ca2+]i and ion secretion via a basolateral P2Y-receptor in rat distal colonic mucosa
Both retatrutide and semaglutide have demonstrated metabolic improvements beyond weight loss, including blood sugar lowering and cholesterol improvement
When compared to those taking topiramate, GLP-1 users were: 48% less likely to start valproate 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies 35% less likely to start tricyclic antidepressants 23% less likely to start the class of drugs called gepants However, there was no significant difference between the two groups, and the need to begin taking beta-blockers
Bottom line: While Wegovy has the backing of large-scale clinical trials for its specific formulation, compounded semaglutide provides a safe, regulated alternative that uses the same active molecule to support weight loss goals
This strategy offers a dual mode of action by combining metabolic regulation through GLP-1R activation with vascular protection mediated by enhanced reverse cholesterol transport [434,435,436]